Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | See Remarks | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,938 |
Last balance in matching sequence
After 2026-10-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-10-01 · Exercise / conversion · Acquired 413 · Balance 10,351 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 2 · 2026-10-01 · Sale · Disposed 413 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 3 · 2026-10-02 · Exercise / conversion · Acquired 24,587 · Balance 34,525 F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 4 · 2026-10-02 · Sale · Disposed 15,843 · Balance 18,682 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Row 5 · 2026-10-02 · Sale · Disposed 8,744 · Balance 9,938 F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction. F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 66,573 |
Reported balance
After 2026-10-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-10-01 · Exercise / conversion · Disposed 413 · Balance 66,573 F11: Fully exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2027-02-10 | Direct | 41,986 |
Reported balance
After 2026-10-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-02 · Exercise / conversion · Disposed 24,587 · Balance 41,986 F11: Fully exercisable. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,147 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,147 F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 20,570 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 20,570 F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 40,000 F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 34,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 34,000 F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 10,000 F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F6: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F7: Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
F8: Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F9: Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
F10: Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F11: Fully exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2024 Filed Mar 29, 2024 18:12 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,953 | $3.88 | $100,697.64 |
DisclosureSEC source: 0000950170-24-038530 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000950170-24-034264 · ownership.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $2.61 | $26,100.00 |
DisclosureSEC source: 0000950170-24-034264 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 19, 2024 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 20 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 79,693 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| March 19, 2024 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 19 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,929 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 17,219 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-034264 · ownership.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,939 Underlying: Common Stock · 17,219 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 17,219 | $25.00 | $430,475.00 |
DisclosureSEC source: 0000950170-24-034264 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,222 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 17,219 | $3.88 | $66,809.72 |
DisclosureSEC source: 0000950170-24-034264 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 636 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026779 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,222 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F2 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 636 | $24.06 | $15,302.16 |
DisclosureSEC source: 0000950170-24-026779 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,586 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F2 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:14 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 505 | $24.06 | $12,150.30 |
DisclosureSEC source: 0000950170-24-026779 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,950 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 14,842 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · derivative · entry 10 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,158 Underlying: Common Stock · 14,842 shares Expires 2026-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (right to buy) · Derivative | 12,226 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,226 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 27,068 | $25.97 | $702,904.53 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,455 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 14,842 | $3.88 | $57,586.96 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 12,226 | $3.29 | $40,223.54 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 4,760 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,226 Underlying: Common Stock · 4,760 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 4,760 | $25.00 | $119,000.00 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,455 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 4,760 | $3.29 | $15,660.40 |
DisclosureSEC source: 0000950170-24-017442 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014883 · ownership.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 14,991 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · derivative · entry 9 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,986 Underlying: Common Stock · 14,991 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,009 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,009 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 582 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · nonDerivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,455 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 582 | $25.97 | $15,114.54 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,873 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics 2012 Incentive Award Plan on December 1, 2023. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $25.56 | $639,047.50 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,291 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.47 to $25.785. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 14,991 | $3.29 | $49,320.39 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,009 | $2.61 | $26,123.49 |
DisclosureSEC source: 0000950170-23-068370 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 19,888 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · derivative · entry 8 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,009 Underlying: Common Stock · 19,888 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 19,888 | $28.11 | $559,055.66 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · nonDerivative · entry 4 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,291 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.08 to $28.1244. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 19,888 | $2.61 | $51,907.68 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 5,112 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,897 Underlying: Common Stock · 5,112 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 5,112 | $28.08 | $143,544.96 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,291 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 5,112 | $2.61 | $13,342.32 |
DisclosureSEC source: 0000950170-23-058936 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0000950170-23-053183 · ownership.xml · derivative · entry 7 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,009 Underlying: Common Stock · 10,000 shares Expires 2024-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 8,471 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-23-053183 · ownership.xml · derivative · entry 6 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,471 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 18,471 | $27.29 | $504,038.50 |
DisclosureSEC source: 0000950170-23-053183 · ownership.xml · nonDerivative · entry 3 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,291 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.435. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. F4 · balance_after: The Form 4 previously filed inadvertently overstated the number of shares held by 319. The number in Column 5 reflects the corrected amount. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 10,000 | $2.61 | $26,100.00 |
DisclosureSEC source: 0000950170-23-053183 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 10, 2023 Filed Oct 13, 2023 00:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 8,471 | $3.02 | $25,582.42 |
DisclosureSEC source: 0000950170-23-053183 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 21:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,498 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-23-052713 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,471 Underlying: Common Stock · 3,498 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 21:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,498 | $27.24 | $95,285.52 |
DisclosureSEC source: 0000950170-23-052713 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,610 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 21:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,498 | $3.02 | $10,563.96 |
DisclosureSEC source: 0000950170-23-052713 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,031 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-23-051899 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,969 Underlying: Common Stock · 3,031 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,031 | $27.24 | $82,576.87 |
DisclosureSEC source: 0000950170-23-051899 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,610 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.255. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:05 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,031 | $3.02 | $9,153.62 |
DisclosureSEC source: 0000950170-23-051899 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 22:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 25,000 | $32.48 | $812,000.00 |
DisclosureSEC source: 0000950170-23-049040 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,610 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $32.32 to $32.70. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 22:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0000950170-23-049040 · ownership.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 25,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 22:07 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 25,000 | $3.02 | $75,500.00 |
DisclosureSEC source: 0000950170-23-049040 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 456 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046808 · ownership.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,610 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:06 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 456 | $33.10 | $15,093.60 |
DisclosureSEC source: 0000950170-23-046808 · ownership.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,154 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Jun 3, 2025 00:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 1,059 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 18 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 69,693 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.